Ireland· IE-PA-PA0686/007/007
Optiray 350 mg I/ml PFS solution for injection
A ioversol product containing ioversol, registered in Ireland by Guerbet. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ioversol is registered in 14 of 19 countries.
Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Ioversol · ATC V08AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Ioversol
- Manufacturer
- Guerbet
- Country
- Ireland (IE)
- ATC code
- V08AB07
- ATC class
- Ioversol
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0686/007/007
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
188 interactions on record for ioversol.
Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ioversol · interactions on record
188 records
- 94 severe
- 55 moderate
- 39 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ioversol in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomOptiray 350 solution for infusion 100ml bottlesGuerbet Laboratories Ltd
- SwedenOptiray (flerdos) 350 mg I/ml Injektions-/infusionsvätska, lösningGuerbet
- BelgiumOptiject 240 mg I/mlGuerbet
- CzechiaOPTIRAYGuerbet, Roissy CdG Cedex
- Japanイオベルソールゲルベ・ジャパン
- FinlandOptirayMallinckrodt Medical GmbH
- SpainOPTIRAY 240 mg/ml SOLUCION INYECTABLEGuerbet
- United StatesOptirayLiebel-Flarsheim Company LLC
Authorised across Europe · EMA
The same active substance is authorised in 21 EEA countries. Names it is sold under:
- Austria · Optiray
- Belgium · Optiject, Optiray
- Czechia · Optiray
- Germany · Optiray
- Denmark · Optiray
- Spain · Optiray, Optiray Ultraject
- Finland · Optiray
- France · Optiject, Optiray
- United Kingdom (Northern Ireland) · Optiray
- Greece · Optiray
- Croatia · Optiray
- Hungary · Optiray
- Italy · Optiray
- Luxembourg · Optiject, Optiray
- Netherlands · Optiray
- Norway · Optiray
- Poland · Optiray
- Portugal · Optiray
- Romania · Optiray
- Sweden · Optiray
- Slovakia · Optiray
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcbe371d-3a6b-4127-af01-337c75fbbaca GET /v1/drugs/bcbe371d-3a6b-4127-af01-337c75fbbaca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"V08AB",
"V08AB07"
],
"strength": null,
"pa_number": "PA0686/007/007",
"substances": [
"Ioversol"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "14/04/2000",
"dispensing_status": "Product subject to Restricted Prescription (C)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ioversol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.